Repros Therapeutics

Repros Therapeutics — Investor Presentation (May 2014)

36 slides from Repros Therapeutics's investor presentation, May 8, 2014

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai

  3. Slide 3: Investment Highlights for 2014

    Investment Highlights for 2014 Significant Value Creating Events for Androxal , An Oral Treatment for Low T Androxal Restores the Body’s ability to Produce Its Own Testosterone • Androxal ® 2014 Milestones – Complete all clinical studies – Complete head - to - head studies of Androxal versus Androge

  4. Slide 4: Testosterone Market and Androxal Overview

    Testosterone Market and Androxal Overview • US market for low testosterone exceeds $1.5 billion • Only approved non invasive therapies are hormone replacements • Repros believes 85% of hypogonadal men experience low T due to an endocrine disorder – These men have functional but un - stimulated teste

  5. Slide 5: Who are the men using testosterone?

    Who are the men using testosterone? European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng / dL LH:

  6. Slide 6: Day to Day Morning T Variability in Men with Secondary Hypogonadism

    Day to Day Morning T Variability in Men with Secondary Hypogonadism Sampling of Placebo Subjects ZA - 003

  7. Slide 7: Estrogen Exogenous Testosterone Override Suppresses LH and FSH

    Estrogen Exogenous Testosterone Override Suppresses LH and FSH

  8. Slide 8: Head to Head Comparison of Two Doses of Androxal to Testim and Placebo

    Head to Head Comparison of Two Doses of Androxal to Testim and Placebo, Study ZA - 203 An approved T gel significantly suppresses LH and FSH in a clinically relevant manner and suppresses sperm concentration to near severe oligospermia (median sperm concentration 6.2 million/mL) after only three mon

  9. Slide 9: Androxal regulatory history timeline

    • July 2002 IND for Androxal to Treat 2 ° Hypogonadism • Nov.’04 24hr Serial Testosterone to determine average and maximum concentration • Nov.’04(+1) Testosterone endpoint not acceptable because Androxal is not testosterone • 2007 Even though Androxal is non inferior to Androgel with numerous advan

  10. Slide 10: Head to Head Studies Comparing Androxal to Androgel 1.62

    Head to Head Studies Comparing Androxal to Androgel 1.62 Endpoints Changed per Late April FDA Guidance • ZA - 304 & ZA - 305: Two identical studies not under SPA – 3 arm parallel design with 40 subjects per arm – 23 US clinical sites – Primary endpoint comparison of Androxal and Androgel with respec

  11. Slide 11: ZA-304 & ZA-305 Efficacy Endpoints

    ZA - 304 & ZA - 305 Efficacy Endpoints Endpoint Class Endpoint Goal Powering Primary % of subjects with sperm concentration <10X10 6 /mL Comparing Androxal to Androgel 1.62% Show Androxal superior to Androgel 10% vs 50% 98.6% % change from baseline comparing Androxal to Androgel 1.62% Show Androxal

  12. Slide 12: Baseline Morning Testosterone

    ZA - 305 Baseline Morning Testosterone (fully enrolled, n=127) Mean Age: 47 Mean BMI: 33.4 Baseline Morning Testosterone (ng/ dL ) n 127 Mean 216.2 Median 214.0 Standard Deviation 54.1 (Minimum, Maximum) (79.0, 299.0)

  13. Slide 13: Baseline Semen Concentration

    ZA - 305 Baseline Semen Concentration 0 2 4 6 8 10 12 14 16 18 20 22 24 15 25 35 45 55 65 75 85 95 100 150 200 250 More Number of Subjects with Baseline Semen Concentration Baseline Semen Concentration Histogram Mean Semen Concentration 78.0 million/mL Median Semen Concentration 61.3 million/mL

  14. Slide 14: Experience with Percentage Change in Semen Concentration

    Experience with Percentage Change in Semen Concentration Androxal (ZA-301) Androxal (ZA-302) Androxal 12.5 mg (ZA-203) Androxal 25 mg (ZA-203) Testim (ZA-203) Median -3.3 -1.3 -19.5 -15.9 -88.2 -100.0 -90.0 -80.0 -70.0 -60.0 -50.0 -40.0 -30.0 -20.0 -10.0 0.0 Median Percentage Change from Baseline in

  15. Slide 15: Median Semen Concentrations

    Median Semen Concentrations in ZA - 203 Baseline 3 Months 1 Week Post Drug 4 Weeks Post Drug 12.5 mg 106.8 60.3 72.5 67.0 25 mg 66.0 47.0 98.8 64.0 Placebo 44.0 77.0 70.4 73.4 Testim 60.0 6.4 2.2 19.3 0.0 20.0 40.0 60.0 80.0 100.0 120.0 Sperm Concentration (million/mL)

  16. Slide 16: Androxal Safety

    Androxal Safety • Generally well tolerated at all doses – >1400 men exposed – >850 men for 6 months – >100 men for 12 months – >650 patient years of exposure • Adverse events consistent with increasing T – No exposure of T outside the normal range • Lower frequency of increased hematocrit 0 1 2 3 4

  17. Slide 17: Excursions Above Normal Range for T Lead to Increasing Hematocrit

    Excursions Above the Normal Range for T Leads to Increasing Hematocrit with T Replacement “Exogenous testosterone (TT) is associated with physiologic changes that predispose to clotting and thrombotic disorders including increased blood pressure [18], polycythemia [19], reductions in HDL cholesterol

  18. Slide 18: 24-Hr Assessment Androgel 1%

    ZA - 204 24 Hr Assessment Androgel 1% 0 500 1000 1500 2000 2500 3000 0 5 10 15 20 Total Testosterone Hours 3 of 13 Subjects in Androgel Arm Exhibited T>1040 2012 2011 2052

  19. Slide 19: 24 Hour T & LH Androxal Subject

    24 Hour T & LH 25 mg Androxal Subject Study ZA - 204 Subject 2 - 003 Age: 55, BMI: 32 Baseline 0 time: 8:09 AM Week 6 0 time: 7:25 AM

  20. Slide 20: ZA-301 Study

    ZA - 300 Study • 499 Subjects randomized – Baseline Morning T < 300 – 23.5% Type II Diabetes – 30.6% taking c holesterol medication – 33.3% previous T exposure • 6 months of treatment • 2 months of follow - up post treatment • 393 Subjects (78.8%) completed study – 23 (4.6%) Withdrew due to an Adver

  21. Slide 21: Testosterone Response

    Testosterone Response g Mean Morning Testosterone (NG/DL) 8 8 Baseline 6Weeks_-—«16 Weeks G Months 4 Weeks Post 8 Weeks Post Drug Drug.

  22. Slide 22: Additional Findings after 6 months of treatment

    ZA - 300 Additional Findings after 6 months of treatment • Androxal improves symptoms of metabolic syndrome – Androxal reduces total cholesterol and improves HDL/LDL ratio – Androxal reduces fasting plasma glucose levels – Androxal shifts A1c into normal range in a statistically significant manner •

  23. Slide 23: Influence of Prior Testosterone

    Influence of Prior Testosterone

  24. Slide 24: ZA-300: Safety

    ZA - 300: Safety • 499 subjects treated with Androxal – For up to 26 weeks • No new safety issues identified – No deaths – No significant cardiovascular findings – No significant eye findings • Venous Thromboembolism – One case (02 - 029) with deep vein thrombosis (DVT) and pulmonary emboli (PE), mu

  25. Slide 25: Two Cases of VTE from ZA-300

    Two Cases of VTE from ZA - 300 39 44 49 54 59 0 50 100 150 200 250 300 350 400 450 Screening Baseline Week 6 Week 16 Morning T Hematocrit 39 44 49 54 59 0 100 200 300 400 500 600 700 Screening Baseline Week 6 Week 16 Week 26 Morning T Hematocrit Subject 02 - 029, 12.5 - 25 mg dose, African American,

  26. Slide 26: Treatment Emergent Cardiac Events

    Treatment Emergent Cardiac Events ZA - 300 EVENT 12.5 mg (N=207)* n (%) 25 mg (N=283)* n (%) CARDIAC DISORDERS 2 (0.97) 2 (0.71) Atrial Flutter 0 (0) 1 (0.35) Bradycardia 2 (0.97) 0 (0) Palpitations 0 (0) 1 (0.35) * Some men withdrew from the study before the first visit after baseline and did not r

  27. Slide 27: Diastolic Blood Pressure

    Diastolic Blood Pressure 90 75 60 g 2 g é 3 3 8 a 15 82.3 825 82.5 83.2 82.2 82.1 p< 0.9823 p< 0.4759 Baseline 6 Months No difference between dose groups (p 12.5 mg 25.0mg Androxal

  28. Slide 28: Androxal Exhibits Unique Profile with Numerous Advantages

    Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Androxal Advantages – Oral – Not controlled substance, cannot be abused – Less CV risk than T’s??? • No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testi

  29. Slide 29: Commercial Goals for Androxal

    Commercial Goals for Androxal • Low T market already at primary care, 75% of written scripts • Specialists readily reached by Repros initiative – Conservative Quintiles assessment full year 1 sales = $120 million using small sales force (n=41) – Cash - flow positive during the first year of launch –

  30. Slide 30: Proellex for Treatment of Uterine Fibroids and Endometriosis

    Proellex for the Treatment of Uterine Fibroids and Endometriosis • Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis • Over 300,000 hysterectomies performed every year in the US to treat these two disorders • No acceptable chronic therap

  31. Slide 31: An Effective Dose of Proellex Stops Menstruation in Majority of Women

    An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone

  32. Slide 32: Proellex Eliminates Endometriosis Pain and Need for Analgesics

    Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline p - value versus placebo 25 mg = 0.001 50 mg = 0.017 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex %

  33. Slide 33: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding and Bulk Symptoms Early Development Results 0 20 40 60 80 100 120 140 160 BL Mo 1 Mo 2 Mo 3 PBAC Score Pictorial Blood Loss Assessment Placebo Proellex 12.5 mg P<0.0001 0 5 10 15 20 25 30 35 40 45 Placebo Pro

  34. Slide 34: Proellex Open Label Extension Study

    ZPV - 200 Ext. Proellex Open Label 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12 mg vaginal dose shrinks fibroids significantly within 8 months of treatment

  35. Slide 35: Proellex Program Status & Goals

    Proellex Program Status & Goals • All Pre - clinical Studies Complete • 60 Subject Phase 2 Low Dose Oral Endometriosis Study Enrolling – Adding foreign sites – Expect full enrollment in the second half of 2014 • Phase 2 Low Dose Oral Fibroid Study Submitted to FDA – Full hold lifted to partial hold

  36. Slide 36: Financial Summary

    Financial Summary • Cash and equivalents (as of 3/31/14, unaudited) $68 M • Cash runway: Through 2016* – Anticipate Androxal approved and launched • Current shares outstanding: 23.1 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 809,805 @ $2.49 exer

Repros Therapeutics — Investor Presentation (May 2014) on 6ix